KR20010085047A - Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan - Google Patents
Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan Download PDFInfo
- Publication number
- KR20010085047A KR20010085047A KR1020010044982A KR20010044982A KR20010085047A KR 20010085047 A KR20010085047 A KR 20010085047A KR 1020010044982 A KR1020010044982 A KR 1020010044982A KR 20010044982 A KR20010044982 A KR 20010044982A KR 20010085047 A KR20010085047 A KR 20010085047A
- Authority
- KR
- South Korea
- Prior art keywords
- chitosan
- soluble chitosan
- molecular weight
- fat diet
- water
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 44
- 235000009200 high fat diet Nutrition 0.000 title claims description 18
- 210000000577 adipose tissue Anatomy 0.000 title abstract description 6
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 150000002632 lipids Chemical class 0.000 claims abstract description 7
- 229920000642 polymer Polymers 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241000238557 Decapoda Species 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 229940088598 enzyme Drugs 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000037396 body weight Effects 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 108010022172 Chitinases Proteins 0.000 abstract description 2
- 102000012286 Chitinases Human genes 0.000 abstract description 2
- 108010014251 Muramidase Proteins 0.000 abstract description 2
- 102000016943 Muramidase Human genes 0.000 abstract description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 229960000274 lysozyme Drugs 0.000 abstract description 2
- 235000010335 lysozyme Nutrition 0.000 abstract description 2
- 239000004325 lysozyme Substances 0.000 abstract description 2
- 108010059892 Cellulase Proteins 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 229940106157 cellulase Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000013505 freshwater Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 108010089807 chitosanase Proteins 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/511—Chitin, chitosan
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
최근 식생활이 서구화되고 생활양식이 편리해짐에 따라 운동 부족 등으로 비만증 환자가 증가하여 사회 문제화되고 있다. 비만증의 대부분은 섭취한 열량 중에서 소모되고 남은 부분이 지방으로 전환되어 체내의 여러 부분, 특히 피하조직과 복강 내에 축적되는 현상이다. 비만증 환자는 지방조직의 기능에 필요한 지방량보다 훨씬 많은 지방이 체내에 축적되어 인체내의 정상적인 생화학적 및 생리적 기능에 장애를 줄 뿐 아니라 여러 가지 질환, 특히 당뇨병, 고지혈증, 고혈압 및 관상동맥질환의 원인이 되기 때문에 예방과 조기치료에 많은 노력을 기울여야만 한다.Recently, as the eating habits are westernized and the lifestyle becomes more convenient, obesity patients increase due to lack of exercise, which is becoming a social problem. Most of the obesity is the consumption of calories consumed and the remaining portion is converted to fat, which accumulates in various parts of the body, especially the subcutaneous tissue and abdominal cavity. In obese patients, much more fat is accumulated in the body than is needed for the function of adipose tissue, which impedes the normal biochemical and physiological functions of the body, and causes various diseases, especially diabetes, hyperlipidemia, hypertension and coronary artery disease. As a result, much effort should be given to prevention and early treatment.
최근 고 콜레스테롤 혈증과 동맥경화 예방 및 치료를 위한 연구의 방향은 비만 및 고지혈증에 직접적인 영향을 미치는 식이에 따른 지방, 콜레스테롤 등의 효과적인 조절 물질을 탐색하는 것이다.Recently, the direction of research for the prevention and treatment of hypercholesterolemia and arteriosclerosis is to search for effective regulators such as fat and cholesterol according to the diet directly affecting obesity and hyperlipidemia.
키토산은 새우, 게 등의 갑각류의 껍질, 갑충의 갑피 등 절족 동물의 외골격, 연체동물의 기관, 곰팡이, 효모, 버섯 등 진균류의 세포벽 등에 함유되어 있다. 그리고 생체 내에서는 탄수화물과 단백질의 결합된 형태로 존재한다. 키토산은 다양한 기능을 발휘하기 때문에 여러 가지 방면으로 연구되고 있다. 예컨데 키토산은 혈액 응고와 관련된 효소를 활성화 시켜 혈액 응고를 촉진하여 지혈 작용을 며, 또한 면역 증진 효과를 나타내여 대식세포의 활동성을 증진시킴으로써 항암효과를 나타내기도 한다. 키토산은 아세틸 (acetyl) 잔기가 양극 (positive charge)을 나타내므로 음극 (negative charge)을 띤 지방이나 지질 등과 결합한다고 알려져 있으며 소화효소에 의해 분해되지 않으므로 식이 섬유와 같은 작용을 나타낸다고 보고된 바 있다.Chitosan is contained in shells of shellfish such as shrimps and crabs, exoskeletons of arthropods such as the shells of beetles, organs of mollusks, cell walls of fungi such as fungi, yeasts, and mushrooms. And in vivo, it is a combined form of carbohydrate and protein. Chitosan has been studied in various ways because it has various functions. For example, chitosan activates an enzyme related to blood coagulation to promote blood coagulation, which acts as a hemostatic effect, and also has an anti-tumor effect by promoting macrophage activity. Chitosan is known to bind to fats and lipids with negative charges because acetyl residues show positive charges and have been reported to act like dietary fiber because they are not degraded by digestive enzymes.
하지만 지금까지의 연구 결과는 대부분 저분자 키토산 혹은 고분자 키토산이지만 수불용용성 키토산에 대한 결과이다. 이런 키토산은 본 연구에서 사용한 고 분자 수용성 키토산에 비해 체내 이용율이 현저히 떨어지기 때문에 실제 임상 환경에서 그 효과가 탁월할 것으로 예상된다. 본 연구는 고분자 수용성 키토산에 의한 고지방 식이유도성 체 지방 증가에 미치는 영향을 실험한 최초의 결과이다.However, the results so far are mostly low-molecular chitosan or high molecular chitosan, but the results are for water-insoluble chitosan. Such chitosan is expected to be excellent in the actual clinical environment because the utilization rate is significantly lower than the high molecular water-soluble chitosan used in this study. This study was the first to test the effects of high molecular weight water-soluble chitosan on high fat dietary body fat.
본 발명자들은 실험동물인 흰쥐 (rats)를 이용하여 고 지방 식이에 따른 혈청 지질 및 체중 증가에 미치는 고분자 수용성 키토산의 효과를 실험한 결과 체 지방 축적이 현격하게 감소하는 것을 확인하였으며 혈청 지질 등의 농도도 감소시켜 체중 감량 효과가 뛰어난 것을 발견하였다.The present inventors confirmed the effect of polymer-soluble chitosan on the serum lipid and weight gain according to the high fat diet using rats, which are experimental animals, and found that body fat accumulation significantly decreased. In addition, the weight loss effect was found to be excellent.
고분자 수용성 키토산 제조방법Manufacturing Method of Polymer Water Soluble Chitosan
새우 및 게의 껍질로부터 얻은 키토산을 산으로 처리한 후 키토시나아제, 키티나제, 셀롤라제 및 라이소자임 중 어느하나 이상의 효소를 0.1내지 15중량％의 농도로 처리하여 수용화시켰다. 상기 효소처리와 병행하여, 10∼40KHz 범위의 주파수에서 시간 20∼90분간 초음파 처리하였ㅂ다.Chitosan obtained from the shells of shrimp and crabs was treated with acid followed by solubilization by treatment of enzymes of at least one of chitocinase, chitinase, celolase and lysozyme at a concentration of 0.1 to 15% by weight. In parallel with the enzyme treatment, sonication was performed for 20 to 90 minutes at a frequency in the range of 10 to 40 KHz.
그 다음 진공 건조시킨 후 순수한 물에 용해시켜, 상기와 같은 초음파 공정을 반복적으로 수행한 다음 정제하 22만∼100만 범위의 평균분자량을 갖는 키토산 혼합물을 얻었다.그후 상기 혼합물을 냉동건조시켜 인체에 흡수될 수 있는 수용성 고분자 키토산을 제조하였다. 이와 같이 하여 제조된 수용성 고분자 키토산을 분자량에 따라 나누면 하기 표1과 같다.It was then dried in vacuo and then dissolved in pure water to repeatedly perform the above ultrasonic process to obtain a chitosan mixture with an average molecular weight in the range of 220,000 to 1 million under purification. The mixture was then lyophilized to the human body. A water soluble polymer chitosan that can be absorbed was prepared. The water-soluble polymer chitosan prepared in this manner is divided into the following Table 1 by molecular weight.
또한 새우 및 게로부터 얻은 키토산에 키토사나아제를 키토산에 대하여 5중량％로 주입함과 동시에 각각 10, 20 및 30KHz로 20, 30, 60, 및 90분간 초음파 처리하여 얻어진 키토산의 평균 분자량은 하기 표2와 같다.In addition, chitosan obtained from shrimp and crab was injected 5% by weight of chitosanase with respect to chitosan, and the average molecular weight of chitosan obtained by sonication at 20, 30, 60, and 90 minutes at 10, 20, and 30 kHz, respectively, is shown in the following table. Same as 2.
상기와 같은 평균 분자량을 갖는 키토산을 제조한후 냉동건조하여 불순물이 없는 평균 분자량 220,000내지 1,000,000인 키토산을 얻었다. 분자량은 GPC (gel permeation Chromatography)로 측정하였다.Chitosan having the above average molecular weight was prepared and freeze-dried to obtain chitosan having an average molecular weight of 220,000 to 1,000,000 without impurities. Molecular weight was measured by GPC (gel permeation Chromatography).
상기 실시예 1 내지 실시예6의 제조공정으로 얻어진 최종제품의 중금속(Pb, As)을 정량 분석 하였다. 납(Pb)과 비소(As)의 정량은 자동흡수 스펙트럼(Atomic absorption spectrometer)(Varian Co. spectraAA-300, USA)을 사용하여 정량해본 바, 매우 양호한 구성물임을 확인 하였다.Heavy metals (Pb, As) of the final product obtained in the manufacturing process of Example 1 to Example 6 were quantitatively analyzed. Determination of lead (Pb) and arsenic (As) was carried out using an atomic absorption spectrometer (Varian Co. spectra AA-300, USA), and found to be a very good component.
또한 초음파공법을 통해 얻어진 고분자 수용성 키토산의 황산화 효과를 대표적인 황산화물인 비타민 C와 비교하였다. 상기 실시예 1 내지 실시예 6의 최종산물을 용액으로 제조하여 실험 하였으며 , 표3에서와 같이 안정한 상태와 우수한 황산화력을 나타내었다. 측정은 UV흡광기(Cary Ⅰ. UV-Visible Spectrophotometer.:Vanan Co. USA)로 하였다.In addition, the sulfated effect of the polymer water-soluble chitosan obtained through the ultrasonic method was compared with the representative sulfur oxide vitamin C. The final product of Example 1 to Example 6 was prepared as a solution and tested, and showed a stable state and excellent sulfate power as shown in Table 3. The measurement was carried out with a UV absorber (Cary I. UV-Visible Spectrophotometer .: Vanan Co. USA).
실시 예 1: 실험동물 및 식이Example 1 Experimental Animals and Diet
실험동물은 Sprague-Dawley 종의 수컷 (190∼200 g) 흰쥐를 5 마리씩 5 군으로 다음과 같이 실험하였다. 정상 군은 정상 식이 군으로 하였고 대조 군은 고 지방 식이 군으로 전체열량의 40 ％를 지방 열량으로 조성하였다. 실험 군은 고 지방 식이에 고분자 수용성 키토산을 1 ％, 10 ％를 첨가하여 사료를 만들었다. 물과 식이는 자유롭게 먹을 수 있도록 하였다.Experimental animals were 5 male rats (190-200 g) of Sprague-Dawley species in 5 groups. The normal group was the normal diet group, and the control group was the high fat diet group, and 40% of the total calories were composed of fat calories. The experimental group made the feed by adding 1% and 10% of polymer water-soluble chitosan to the high fat diet. Water and diet were free to eat.
실험 예 1: 체중측정Experimental Example 1: Weight Measurement
20 일 동안 5 일에 한번씩 체중 증가량을 측정하였다. 실험 결과 그림 1에서 볼 수 있듯이 고 지방 식이 군의 체중은 정상 식이 군에 비해 20 일 후 약 4.6 ％증가하였으며 고 지방 식이에 고분자 수용성 키토산을 1 ％ 첨가한 그룹은 별다른 변화가 없었다. 고 지방 식이에 고분자 수용성 키토산을 10 ％ 첨가한 그룹의 평균 체중은 고지방 식이를 한 그룹에 비하여 20 일 후 약 12％ 감소하는 효과를 확인하였다.Weight gain was measured once every 5 days for 20 days. As shown in Fig. 1, the body weight of the high fat diet group increased by about 4.6% after 20 days compared to the normal diet group, and there was no change in the high fat diet group with 1% polymer water soluble chitosan. The average body weight of the group in which 10% of the polymer-soluble chitosan was added to the high fat diet was confirmed to be reduced by about 12% after 20 days compared to the high fat diet group.
[그림1] 고분자 수용성 키토산 섭취 시 흰쥐의 체중 변화[Figure 1] Changes in the weight of rats after ingestion of water-soluble chitosan
CON- 정상식이군CON- Normal diet
FAT- 고지방식이군It's FAT-high
CHI1- 고지방식이+고분자 수용성 키토산 1％CHI1- High Fat Diet + Polymer Water Soluble Chitosan 1%
CHI10- 고지방식이+고분자 수용성 키토산 10％CHI10- High Fat Diet + Polymer Water Soluble Chitosan 10%
실험 예 2: 혈청 중 지질 및 단백 함량 분석Experimental Example 2: Analysis of Lipid and Protein Content in Serum
20 일간의 실험식이 후 12 시간동안 절식시키고 에틸에테르로 마취시킨 후 개복하여 심실에서 1 회용 주사기를 이용하여 혈액을 채취하였으며, 3000 rpm으로 20분간 원심 분리하여 얻은 혈청을 시료로 사용하였다. 혈청의 지질 성분인 total cholesterol, triglyceride 및 albumin 단백 함량을 측정하였다.After the 20-day diet was fasted for 12 hours, anesthetized with ethyl ether, and then opened, blood was collected by a disposable syringe in the ventricles, and serum obtained by centrifugation at 3000 rpm for 20 minutes was used as a sample. The total cholesterol, triglyceride and albumin protein contents of serum lipids were measured.
실험 결과 표 1에 나타낸 바와 고 지방 식이 군의 total cholesterol은 정상 식이 군에 비해 28.8 ％ 증가하였으며 고 지방 식이에 고분자 수용성 키토산 1 ％, 10 ％를 첨가한 그룹은 고 지방식이 에 비해 각각 8.2 ％, 0.7 ％ 감소하였다. triglyceride는 고 지방 식이 군이 정상 식이 군에 비해 6.3 ％ 증가하였으며 고 지방 식이에 고분자 수용성 키토산을 1 ％, 10 ％ 첨가한 식이 군은 고 지방 식이 군에 비해 각각 31.9％, 22.8％ 감소하였다. 이런 결과는 고분자 수용성 키토산 1％ 만으로도 현저한 억제 효과를 나타내기 때문에 및 알부민 함량 수준이 효과적으로 조절될 수 있음을 의미한다.As shown in Table 1, the total cholesterol of the high fat diet group was increased by 28.8% compared to the normal diet group, and the high fat diet group added 1% and 10% high molecular water-soluble chitosan to 8.2%, respectively. 0.7% decrease. The triglyceride was increased by 6.3% in the high fat diet group and 31.9% and 22.8% in the high fat diet group compared with the high fat diet group by 1% and 10%, respectively. These results indicate that only 1% of the polymer water-soluble chitosan exhibits a significant inhibitory effect, and that the albumin content level can be effectively controlled.
이상의 실험 결과에서 알 수 있듯이 본 발명에 사용한 고분자 수용성 키토산은 고 지방 식이에 의한 과 체중의 감량 효과 및 혈청 중 지질, 단백질의 농도를 감소시키는 물질로 유용하게 사용될 수 있다.As can be seen from the above experimental results, the polymer water-soluble chitosan used in the present invention can be usefully used as a substance for reducing the effect of overweight due to a high fat diet and reducing the concentration of lipids and proteins in serum.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010044982A KR20010085047A (en) | 2001-07-25 | 2001-07-25 | Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010044982A KR20010085047A (en) | 2001-07-25 | 2001-07-25 | Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010085047A true KR20010085047A (en) | 2001-09-07 |
Family
ID=19712542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020010044982A KR20010085047A (en) | 2001-07-25 | 2001-07-25 | Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20010085047A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010085046A (en) * | 2001-07-25 | 2001-09-07 | 장태순 | Effects of high molecular weight water-soluble chitosan on ovarian reaction and pregnancy in obesity mice. |
| KR100481793B1 (en) * | 2002-05-24 | 2005-04-11 | 주식회사 만나피아 | A manufacturing method of water soluble chitosan |
| KR20190034122A (en) * | 2017-09-22 | 2019-04-01 | 부산대학교 산학협력단 | Microneedle and its composition for treatment of partial obesity |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06321787A (en) * | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | Carbohydrate absorption-inhibiting agent |
| US5453282A (en) * | 1992-03-24 | 1995-09-26 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
| WO1998034625A1 (en) * | 1997-02-06 | 1998-08-13 | Novasso Oy | Substance and method for reduction of lipids and cholesterol |
| JPH11147828A (en) * | 1997-11-17 | 1999-06-02 | Koji Kashima | Absorption inhibitor against cholesterol and lipid |
| KR20010085046A (en) * | 2001-07-25 | 2001-09-07 | 장태순 | Effects of high molecular weight water-soluble chitosan on ovarian reaction and pregnancy in obesity mice. |
-
2001
- 2001-07-25 KR KR1020010044982A patent/KR20010085047A/en not_active Application Discontinuation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453282A (en) * | 1992-03-24 | 1995-09-26 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
| JPH06321787A (en) * | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | Carbohydrate absorption-inhibiting agent |
| WO1998034625A1 (en) * | 1997-02-06 | 1998-08-13 | Novasso Oy | Substance and method for reduction of lipids and cholesterol |
| JPH11147828A (en) * | 1997-11-17 | 1999-06-02 | Koji Kashima | Absorption inhibitor against cholesterol and lipid |
| KR20010085046A (en) * | 2001-07-25 | 2001-09-07 | 장태순 | Effects of high molecular weight water-soluble chitosan on ovarian reaction and pregnancy in obesity mice. |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010085046A (en) * | 2001-07-25 | 2001-09-07 | 장태순 | Effects of high molecular weight water-soluble chitosan on ovarian reaction and pregnancy in obesity mice. |
| KR100481793B1 (en) * | 2002-05-24 | 2005-04-11 | 주식회사 만나피아 | A manufacturing method of water soluble chitosan |
| KR20190034122A (en) * | 2017-09-22 | 2019-04-01 | 부산대학교 산학협력단 | Microneedle and its composition for treatment of partial obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7776843B2 (en) | Therapeutic uses of glucan | |
| CN101063161A (en) | Coproduction technique for collagen and chondroitin sulfate | |
| JP2009510234A (en) | Abalone polysaccharide extraction method | |
| Rodahl | Hypervitaminosis A in the Rat Eighteen Figures | |
| JP3714426B2 (en) | Cancer metastasis inhibitor containing fucoidan oligosaccharide composition | |
| EA007565B1 (en) | Use of bile acid or bile salt fatty acid compounds for the treatment of fatty lever infiltration | |
| CN114716523B (en) | Millet prolamin peptides with alpha-glucosidase inhibitory activity | |
| US5876762A (en) | Process for obtaining medically active fractions from sea cucumbers | |
| CN116173175A (en) | Preparation method of blood perfusion filler for treating immunodeficiency-induced tumors | |
| US5770205A (en) | Tissue fractions of sea cucumber for the treatment of inflammation | |
| KR20010085047A (en) | Inhibitory Effect of Body Fat Gain by a High-Fat Diet of High Molecular Weight Water-soluble Chitosan | |
| KR101209912B1 (en) | Method of isolation of collagen and collagen isolated by thereof | |
| KR101248617B1 (en) | A method of extracting collagen by ultrasonication | |
| JP4233029B2 (en) | Maitake extract, glycoprotein, and production method thereof | |
| US3211616A (en) | N, o-sulfated neutral-mucopolysaccharide | |
| Pivnenko et al. | The Composition of Collagen-Containing Preparations from Rhopilema asamushi Uchida Jellyfish and Assessment of the Safety of their External Use | |
| JP2838862B2 (en) | Hypoglycemic agent | |
| JPH0670085B2 (en) | Chondroitin sulfate derivative | |
| Mavlonov et al. | Low molecular fucoidan and its macromolecular complex with bee venom melittin | |
| CN116987181B (en) | High biological activity natural hirudin and method for preparing same in high yield | |
| RU2816316C1 (en) | Method of producing food mineral-protein supplement purified from lipid impurities from bivalve molluscs of genus anadara | |
| CA2201768A1 (en) | Powdery biogenic preparation from ossified deer antlers and a food additive based on said biogenic preparation | |
| Junker et al. | Effect of D‐penicillamine on collagen, glycosaminoglycans, DNA and RNA of granulation tissue and connective tissue of skin, bone and aorta in rats | |
| RU2738448C2 (en) | Method for producing and using a biological active additive based on proteoglycans and glycosaminoglycans | |
| RU2752509C1 (en) | Method for producing insulin-containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |